Carl Zeiss Meditec AG

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: DE0005313704
EUR
24.32
-99.68 (-80.39%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

221.96 k

Shareholding (Sep 2025)

FII

0.00%

Held by 1 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Poor long term growth as Net Sales has grown by an annual rate of 7.48% and Operating profit at 8.39% over the last 5 years

 
2

With ROE of 4.82%, it has a Very Expensive valuation with a 1.97 Price to Book Value

3

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 2,175 Million ()

stock-summary
P/E

21.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

2.26%

stock-summary
Debt Equity

0.22

stock-summary
Return on Equity

4.72%

stock-summary
Price to Book

1.03

Revenue and Profits:
Net Sales:
290 Million
(Quarterly Results - Sep 2016)
Net Profit:
31 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-72.98%
0%
-72.98%
6 Months
-71.39%
0%
-71.39%
1 Year
-78.52%
0%
-78.52%
2 Years
-69.5%
0%
-69.5%
3 Years
-54.88%
0%
-54.88%
4 Years
-31.49%
0%
-31.49%
5 Years
-1.86%
0%
-1.86%

Carl Zeiss Meditec AG for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
7.48%
EBIT Growth (5y)
8.39%
EBIT to Interest (avg)
45.11
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
0.23
Sales to Capital Employed (avg)
0.51
Tax Ratio
29.41%
Dividend Payout Ratio
34.09%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
19.29%
ROE (avg)
11.67%

Valuation key factors

Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
1.00
EV to EBIT
16.75
EV to EBITDA
14.81
EV to Capital Employed
1.00
EV to Sales
2.37
PEG Ratio
0.40
Dividend Yield
2.54%
ROCE (Latest)
5.96%
ROE (Latest)
4.72%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
Bearish
Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'16 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2016 is -0.55% vs 23.74% in Sep 2015",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2016 is 191.51% vs -40.45% in Sep 2015",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'16",
        "Sep'15",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "289.80",
          "val2": "291.40",
          "chgp": "-0.55%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "49.90",
          "val2": "45.60",
          "chgp": "9.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.70",
          "val2": "0.40",
          "chgp": "75.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "30.90",
          "val2": "10.60",
          "chgp": "191.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "151.30%",
          "val2": "141.10%",
          "chgp": "1.02%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Sep 2025 is 7.82% vs -1.11% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Sep 2025 is -21.03% vs -38.29% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,227.60",
          "val2": "2,066.10",
          "chgp": "7.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "383.20",
          "val2": "363.50",
          "chgp": "5.42%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "26.60",
          "val2": "29.40",
          "chgp": "-9.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-19.30",
          "val2": "-19.20",
          "chgp": "-0.52%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "142.30",
          "val2": "180.20",
          "chgp": "-21.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "115.30%",
          "val2": "111.70%",
          "chgp": "0.36%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'16 - YoYstock-summary

Sep'16
Sep'15
Change(%)
Net Sales
289.80
291.40
-0.55%
Operating Profit (PBDIT) excl Other Income
49.90
45.60
9.43%
Interest
0.70
0.40
75.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
30.90
10.60
191.51%
Operating Profit Margin (Excl OI)
151.30%
141.10%
1.02%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Sep 2016 is -0.55% vs 23.74% in Sep 2015

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Sep 2016 is 191.51% vs -40.45% in Sep 2015

Annual Results Snapshot (Consolidated) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
2,227.60
2,066.10
7.82%
Operating Profit (PBDIT) excl Other Income
383.20
363.50
5.42%
Interest
26.60
29.40
-9.52%
Exceptional Items
-19.30
-19.20
-0.52%
Consolidate Net Profit
142.30
180.20
-21.03%
Operating Profit Margin (Excl OI)
115.30%
111.70%
0.36%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Sep 2025 is 7.82% vs -1.11% in Sep 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Sep 2025 is -21.03% vs -38.29% in Sep 2024

stock-summaryCompany CV
About Carl Zeiss Meditec AG stock-summary
stock-summary
Carl Zeiss Meditec AG
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available